beta bionics inc - BBNX
BBNX
Close Chg Chg %
16.99 0.80 4.71%
Closed Market
17.79
+0.80 (4.71%)
Volume: 1.79M
Last Updated:
Jan 15, 2026, 4:00 PM EDT
Company Overview: beta bionics inc - BBNX
BBNX Key Data
| Open $16.62 | Day Range 16.25 - 17.86 |
| 52 Week Range N/A - N/A | Market Cap $747.98M |
| Shares Outstanding 44.02M | Public Float 33.43M |
| Beta 5.74 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.79 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.43M |
BBNX Performance
| 1 Week | -11.67% | ||
| 1 Month | -39.18% | ||
| 3 Months | -11.14% | ||
| 1 Year | N/A | ||
| 5 Years | N/A |
BBNX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About beta bionics inc - BBNX
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
BBNX At a Glance
Beta Bionics, Inc.
11 Hughes
Irvine, California 92618
| Phone | 1-949-427-7785 | Revenue | 65.12M | |
| Industry | Medical Specialties | Net Income | -54,756,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 442.926% | |
| Fiscal Year-end | 12 / 2025 | Employees | 291 | |
| View SEC Filings |
BBNX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
BBNX Efficiency
| Revenue/Employee | 223,793.814 |
| Income Per Employee | -188,164.948 |
| Receivables Turnover | 5.429 |
| Total Asset Turnover | 0.502 |
BBNX Liquidity
| Current Ratio | 6.285 |
| Quick Ratio | 5.656 |
| Cash Ratio | 4.898 |
BBNX Profitability
| Gross Margin | 55.107 |
| Operating Margin | -69.484 |
| Pretax Margin | -84.08 |
| Net Margin | -84.08 |
| Return on Assets | -42.171 |
| Return on Equity | -81.348 |
| Return on Total Capital | -65.759 |
| Return on Invested Capital | -76.397 |
BBNX Capital Structure
| Total Debt to Total Equity | 9.544 |
| Total Debt to Total Capital | 8.713 |
| Total Debt to Total Assets | 4.848 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 6.877 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Beta Bionics Inc - BBNX
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
Sales/Revenue
| - | 179.00K | 11.99M | 65.12M | |
Sales Growth
| - | - | +6,601.12% | +442.93% | - |
Cost of Goods Sold (COGS) incl D&A
| - | 2.09M | 5.69M | 29.24M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | 2.09M | 2.09M | 2.28M | |
Depreciation
| - | 2.09M | 2.09M | 2.28M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | +172.50% | +414.08% | - |
Gross Income
| - | (1.91M) | 6.31M | 35.89M | |
Gross Income Growth
| - | - | +430.61% | +468.93% | - |
Gross Profit Margin
| - | -1,065.92% | +52.59% | +55.11% |
| 2022 | 2023 | 2024 | 5-year trend | ||
|---|---|---|---|---|---|
SG&A Expense
| - | 63.94M | 42.16M | 81.14M | |
Research & Development
| - | 31.43M | 17.94M | 26.18M | |
Other SG&A
| - | 32.51M | 24.21M | 54.95M | |
SGA Growth
| - | - | -34.06% | +92.46% | - |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (911.00K) | 9.96M | 13.41M | |
EBIT after Unusual Expense
| - | (64.93M) | (45.81M) | (58.66M) | |
Non Operating Income/Expense
| - | 182.00K | 1.71M | 3.91M | |
Non-Operating Interest Income
| - | 196.00K | 1.78M | 3.91M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| - | (64.75M) | (44.10M) | (54.76M) | |
Pretax Income Growth
| - | - | +31.89% | -24.17% | - |
Pretax Margin
| - | -36,173.74% | -367.64% | -84.08% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| - | (64.75M) | (44.10M) | (54.76M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| - | (64.75M) | (44.10M) | (54.76M) | |
Net Income Growth
| - | - | +31.89% | -24.17% | - |
Net Margin Growth
| - | -36,173.74% | -367.64% | -84.08% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| - | (64.75M) | (44.10M) | (54.76M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| - | (64.75M) | (44.10M) | (54.76M) | |
EPS (Basic)
| - | -1.5108 | -1.0289 | -1.2632 | |
EPS (Basic) Growth
| - | - | +31.90% | -22.77% | - |
Basic Shares Outstanding
| - | 42.86M | 42.86M | 43.35M | |
EPS (Diluted)
| - | -1.5108 | -1.0289 | -1.2632 | |
EPS (Diluted) Growth
| - | - | +31.90% | -22.77% | - |
Diluted Shares Outstanding
| - | 42.86M | 42.86M | 43.35M | |
EBITDA
| - | (63.76M) | (33.76M) | (42.97M) | |
EBITDA Growth
| - | - | +47.05% | -27.28% | - |
EBITDA Margin
| - | -35,618.44% | -281.44% | -65.98% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 32.60 | |
| Number of Ratings | 10 | Current Quarters Estimate | -0.463 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -1.741 | |
| Last Quarter’s Earnings | -0.375 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.945 | Next Fiscal Year Estimate | -1.718 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 10 | 9 |
| Mean Estimate | -0.46 | -0.44 | -1.74 | -1.72 |
| High Estimates | -0.34 | -0.35 | -1.27 | -0.88 |
| Low Estimate | -0.64 | -0.61 | -2.33 | -2.38 |
| Coefficient of Variance | -20.53 | -20.14 | -18.84 | -29.58 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 9 | 9 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Beta Bionics Inc - BBNX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Beta Bionics Inc - BBNX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 7, 2026 | Michael Robert Mensinger Chief Product Officer | 83,552 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $29.56 per share | 2,469,797.12 |
| Jan 7, 2026 | Michael Robert Mensinger Chief Product Officer | 82,952 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30.2 per share | 2,505,150.40 |
| Jan 7, 2026 | Stephen Feider Chief Financial Officer | 62,614 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $5.1 per share | 319,331.40 |
| Jan 7, 2026 | Stephen Feider Chief Financial Officer | 42,614 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $29.53 per share | 1,258,391.42 |
| Jan 7, 2026 | Stephen Feider Chief Financial Officer | 49,695 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 28, 2025 | Gerard J. Michel Director | 12,547 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Sean D Carney Director | 11,247 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Danny L. Dearen Director | 11,247 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Maria Palasis Director | 11,247 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Christy Jones Director | 11,247 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Adam Lezack Director | 11,247 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |